These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31028363)

  • 1. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
    Eich ML; Rodriguez Pena MDC; Springer SU; Taheri D; Tregnago AC; Salles DC; Bezerra SM; Cunha IW; Fujita K; Ertoy D; Bivalacqua TJ; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
    Mod Pathol; 2019 Oct; 32(10):1544-1550. PubMed ID: 31028363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.
    Rodriguez Pena MDC; Tregnago AC; Eich ML; Springer S; Wang Y; Taheri D; Ertoy D; Fujita K; Bezerra SM; Cunha IW; Raspollini MR; Yu L; Bivalacqua TJ; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
    Virchows Arch; 2017 Dec; 471(6):761-767. PubMed ID: 28597078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
    Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
    J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
    Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
    Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
    Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
    Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
    Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
    Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
    Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
    Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.
    Springer SU; Chen CH; Rodriguez Pena MDC; Li L; Douville C; Wang Y; Cohen JD; Taheri D; Silliman N; Schaefer J; Ptak J; Dobbyn L; Papoli M; Kinde I; Afsari B; Tregnago AC; Bezerra SM; VandenBussche C; Fujita K; Ertoy D; Cunha IW; Yu L; Bivalacqua TJ; Grollman AP; Diaz LA; Karchin R; Danilova L; Huang CY; Shun CT; Turesky RJ; Yun BH; Rosenquist TA; Pu YS; Hruban RH; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Dickman KG; Netto GJ
    Elife; 2018 Mar; 7():. PubMed ID: 29557778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Roggisch J; Ecke T; Koch S
    Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.